Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373435 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
A Phase 2 study, sponsored by Eiger BioPharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT03373435 is a Phase 2 study that has completed, run by Eiger BioPharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT03373435, a Phase 2 study, has completed, sponsored by Eiger BioPharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).
Interventions
- OTHER Placebo
- DRUG exendin 9-39
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373435
The ClinicalTrials.gov registry entry for NCT03373435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eiger BioPharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03373435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03373435 about?
NCT03373435 is a clinical study titled "Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia". This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).
What is the current status of trial NCT03373435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2018-03-19. Estimated completion is 2019-03-15.
What interventions are being tested in trial NCT03373435?
The interventions under investigation include: Placebo (OTHER), exendin 9-39 (DRUG).
Who is sponsoring clinical trial NCT03373435?
This trial is sponsored by Eiger BioPharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.